Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes

Barbara Alicja Jereczek-Fossa, Giuseppe Fanetti, Cristiana Fodor, Delia Ciardo, Luigi Santoro, Claudia Maria Francia, Matteo Muto, Alessia Surgo, Dario Zerini, Giulia Marvaso, Giorgia Timon, Paola Romanelli, Elena Rondi, Stefania Comi, Federica Cattani, Federica Golino, Stefano Mazza, Deliu Victor Matei, Matteo Ferro, Gennaro MusiFranco Nolè, Ottavio de Cobelli, Piet Ost, Roberto Orecchia

Research output: Contribution to journalArticlepeer-review


Stereotactic body radiotherapy is being investigated in nodal oligometastatic prostate cancer recurrences as an alternative to systemic treatment. This approach yields excellent in-field control and a low toxicity profile. In selected cases, this approach might also defer palliative androgen deprivation therapy. Background The purpose of the study was to evaluate the prostate serum antigen (PSA) response, local control, progression-free survival (PFS), and toxicity of stereotactic body radiotherapy (SBRT) for lymph node (LN) oligorecurrent prostate cancer. Patients and Methods Between May 2012 and October 2015, 124 lesions were treated in 94 patients with a median dose of 24 Gy in 3 fractions. Seventy patients were treated for a single lesion and 25 for > 1 lesion. In 34 patients androgen deprivation (AD) was combined with SBRT. We evaluated biochemical response according to PSA level every 3 months after SBRT: a 3-month PSA decrease from pre-SBRT PSA of more than 10% identified responder patients. In case of PSA level increase, imaging was performed to evaluate clinical progression. Toxicity was assessed every 6 to 9 months after SBRT. Results Median follow-up was 18.5 months. In 13 patients (14%) Grade 1 to 2 toxicity was reported without any Grade 3 to 4 toxicity. Biochemical response, stabilization, and progression were observed in 64 (68%), 10 (11%), and 20 (21%) of 94 evaluable patients. Clinical progression was observed in 31 patients (33%) after a median time of 8.1 months. In-field progression occurred in 12 lesions (9.7%). Two-year local control and PFS rates were 84% and 30%, respectively. Age older than 75 years correlated with better biochemical response rate. Age older than 75 years, concomitant AD administered up to 12 months, and pelvic LN involvement correlated with longer PFS. Conclusion SBRT is safe and offers good in-field control. At 2 years after SBRT, 1 of 3 patients is progression-free. Further investigation is warranted to identify patients who benefit most from SBRT and to define the optimal combination with AD.

Original languageEnglish
Pages (from-to)e623-e632
JournalClinical Genitourinary Cancer
Issue number4
Publication statusPublished - Aug 1 2017


  • Lymph node recurrence
  • Oligometastases
  • Recurrent prostate cancer
  • Robotic stereotactic radiotherapy
  • Salvage radioablation

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes'. Together they form a unique fingerprint.

Cite this